Marly

Researchers are exploring the role of Acid-Sensing Ion Channels, especially Acid-Sensing Ion Channel-1, in migraine with aura. This study is a Phase 2 proof-of-concept trial aiming to evaluate the potential of amiloride, a non-selective blocker of Acid-Sensing Ion Channel-1, to prevent migraine attacks with aura. Previous findings in animal models and open-label patient series suggest that blocking these channels may reduce migraine aura occurrences. Participants receive treatment by amiloride or placebo in a randomized crossover design, allowing each participant to receive both treatments in sequence. The study is conducted in three French headache centers and compares the effects of amiloride versus placebo on migraine aura frequency. The crossover design helps to directly assess the preventive impact of amiloride on migraine aura. During the 12-week treatment periods, researchers count the number of migraine attacks with aura, with or without headache, as the primary outcome measure. Participants are monitored for compliance and safety, with attention to any side effects or contraindications related to amiloride. The study includes adults aged 18 to 80 years who experience at least one migraine aura per month and meet other eligibility criteria.